Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01178697

Enrollment

Unknown

Registered

2010-08-10

Start date

2010-01-31

Completion date

2010-12-31

Last updated

2010-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion

Brief summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Interventions

DRUGBevasizumab

Intravitreal, 1.25 mg, 3 times, one month apart.

DRUGTriamcinolone Acetonide

Intravitreal, 2 mg, 2 times, two months apart.

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Recent onset (less than 3 months) central retinal vein occlusion

Exclusion criteria

* Any previous intervention

Design outcomes

Primary

Measure	Time frame
Visual acuity	6 months

Secondary

Measure	Time frame
central macular thickness	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026